New wrinkle treatment shows promise in asian trial

NCT ID NCT06308198

Completed Symptom relief Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 3 study tested an investigational botulinum toxin injection called AGN-151586 against a placebo for treating moderate to severe frown lines (glabellar lines). About 160 adults in China, Taiwan, and Japan received either the active injection or a placebo into five points between the eyebrows. The study measured how well the treatment reduced wrinkle severity and monitored side effects. Results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AGN-151586 (botulinum toxin type A injection)
What this could lead to: If it works, this could offer a new option for temporarily reducing frown lines between the eyebrows.
What could go wrong: This is a completed Phase 3 trial, but results are not yet published. As with any injection, side effects like bruising, pain, or temporary muscle weakness are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLABELLAR LINES

Contacts and locations

Locations

Beijing Hospital /ID# 256084

Beijing, Beijing Municipality, 100730, China
Dermatology Hospital of Southern Medical University /ID# 256172

Guangzhou, Guangdong, 510091, China
Huashan Hospital, Fudan University /ID# 255870

Shanghai, Shanghai Municipality, 200040, China
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 260669

Kaohsiung City, 807, Taiwan
Nanjing Drum Tower Hospital /ID# 255936

Nanjing, Jiangsu, 210008, China
Tokyo Center Clinic /ID# 267380

Chuo-ku, Tokyo, 103-0027, Japan
Tri-Service General Hospital /ID# 260673

Taipei, 11490, Taiwan
Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 255871

Wuhan, Hubei, 430022, China
Wuxi People's Hospital /ID# 256029

Wuxi, Jiangsu, 214023, China
Xianyang Hospital of Yan'an University /ID# 256774

Xianyang, Shaanxi, 712000, China
Zhejiang Provincial People's Hospital /ID# 256028

Hangzhou, Zhejiang, 310014, China
Zhongda Hospital Southeast University /ID# 255937

Nanjing, Jiangsu, 210009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.